tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA
Intellia Therapeutics
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
Chart
Earnings
Dividends
Ownership
Financials
News & Insights
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding NTLA?
Track your performance easily
Link Broker

Intellia Therapeutics (NTLA) Stock News & Sentiment

2,842 Followers
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
Premium
Press Releases
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
8d ago
NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16d ago
NTLA
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Premium
Press Releases
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
1M ago
NTLA
NTLA Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
NTLA Upcoming Earnings Report: What to Expect?
1M ago
NTLA
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
Premium
Press Releases
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
2M ago
NTLA
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
Premium
Press Releases
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
2M ago
NTLA
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2M ago
NTLA
More NTLA News >

NTLA News on the Web

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema  at the 2024 ACAAI Annual Scientific Meeting
Yahoo Finance
Neutral
Intellia Therapeutics, Inc.'s latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures
Yahoo Finance
Neutral
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635
Yahoo Finance
Neutral
Guru Fundamental Report for NTLA - Benjamin Graham
Validea
Neutral
Intellia Therapeutics, Inc. : Pioneering Gene Editing Solutions for Health Advancements
Yahoo Finance
Neutral
Intellia Therapeutics, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Yahoo Finance
Neutral
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
Zacks
Neutral
Intellia's Q2 Earnings & Revenues Fall Shy of Estimates
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
NTLA
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NTLA’s Media Buzz Sentiment?
Currently, no data Available
What is NTLA’s weekly average amount of articles?
Currently, no data Available
What is NTLA’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
EPIXESSA Pharma
NUVLNuvalent
BLCOBausch + Lomb Corporation
INCYIncyte
ACRVAcrivon Therapeutics, Inc.
Showing the stocks with the most bullish news sentiment over the past week

Become an Expert with TipRanks Premium

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis
Subscribe NowSee Plans & Pricing